BioPharmSignal logoBioPharmSignal

Biotech News

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

Cabaletta Bio (CABA)Cabaletta BioCompany update

CABA (CABA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is caba.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

CABACabaletta Bio2026-06-03 11:00 EST

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

CABACabaletta Bio2026-08-13 11:30 EST

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

CLDXCelldex Therapeutics2026-06-10 20:01 EST

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

KYTXKyverna Therapeutics2026-07-27 12:00 EST

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel

INMBINmune Bio2026-08-06 20:00 EST

INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress

CLDXCelldex Therapeutics2026-06-14 09:15 EST

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

SABSSAB Biotherapeutics2026-05-29 12:00 EST

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

INMBINmune Bio2026-07-20 11:00 EST

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

BMYBMYBristol-Myers Squibb Company2026-08-10 13:01 EST

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

View all latest news

Cabaletta Bio

Autoimmune Cell Therapy Company Cabaletta Bio develops engineered T-cell therapies intended to produce deep and durable responses in autoimmune disease. Rese-cel Rese-cel is a fully human CD19-directed CAR T-cell therapy being studied across myositis, systemic lupus erythematosus, systemic sclerosis, and pemphigus vulgaris. CARTA...

Recent company news

CABACabaletta Bio2026-08-13 11:30 EST

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

CABACabaletta Bio2026-06-03 11:00 EST

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

CABACabaletta Bio2026-05-14 11:05 EST

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

CABACabaletta Bio2026-05-14 11:00 EST

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

CABACabaletta Bio2026-05-04 10:35 EST

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Stock data

Close
3.13 USD
Market cap
600.04M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States